| Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis RB Jones, JW Cohen Tervaert, T Hauser, R Luqmani, MD Morgan, ... New England Journal of Medicine 363 (3), 211-220, 2010 | 1960 | 2010 |
| Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension M Walsh, PJ Devereaux, AX Garg, A Kurz, A Turan, RN Rodseth, ... Anesthesiology 119 (3), 507-515, 2013 | 1470 | 2013 |
| Discrimination and Calibration of Clinical Prediction Models: Users’ Guides to the Medical Literature AC Alba, T Agoritsas, M Walsh, S Hanna, A Iorio, PJ Devereaux, ... Jama 318 (14), 1377-1384, 2017 | 1090 | 2017 |
| Long-term patient survival in ANCA-associated vasculitis O Flossmann, A Berden, K de Groot, C Hagen, L Harper, C Heijl, ... Annals of the rheumatic diseases 70 (3), 488-494, 2011 | 957 | 2011 |
| Myocardial Injury after Noncardiac Surgery: A Large, International, Prospective Cohort Study Establishing Diagnostic Criteria, Characteristics, Predictors, and 30-day Outcomes F Botto, P Alonso-Coello, MTV Chan, JC Villar, D Xavier, S Srinathan, ... Anesthesiology 120 (3), 564-578, 2014 | 923 | 2014 |
| Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial BF Culleton, M Walsh, SW Klarenbach, G Mortis, N Scott-Douglas, ... Jama 298 (11), 1291-1299, 2007 | 791 | 2007 |
| Association of postoperative high-sensitivity troponin levels with myocardial injury and 30-day mortality among patients undergoing noncardiac surgery PJ Devereaux, BM Biccard, A Sigamani, D Xavier, MTV Chan, ... Jama 317 (16), 1642-1651, 2017 | 732 | 2017 |
| Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody–associated vasculitis: A randomized controlled trial TF Hiemstra, M Walsh, A Mahr, CO Savage, K De Groot, L Harper, ... Jama 304 (21), 2381-2388, 2010 | 650 | 2010 |
| Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis M Walsh, PA Merkel, CA Peh, WM Szpirt, X Puéchal, S Fujimoto, ... New England Journal of Medicine 382 (7), 622-631, 2020 | 609 | 2020 |
| Avacopan for the treatment of ANCA-associated vasculitis DRW Jayne, PA Merkel, TJ Schall, P Bekker New England Journal of Medicine 384 (7), 599-609, 2021 | 594 | 2021 |
| The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index M Walsh, SK Srinathan, DF McAuley, M Mrkobrada, O Levine, C Ribic, ... Journal of clinical epidemiology 67 (6), 622-628, 2014 | 555 | 2014 |
| Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up L Harper, MD Morgan, M Walsh, P Hoglund, K Westman, O Flossmann, ... Annals of the rheumatic diseases 71 (6), 955-960, 2012 | 506 | 2012 |
| Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta … SC Palmer, B Tendal, RA Mustafa, PO Vandvik, S Li, Q Hao, D Tunnicliffe, ... bmj 372, 2021 | 495 | 2021 |
| Risk factors for relapse of antineutrophil cytoplasmic antibody–associated vasculitis M Walsh, O Flossmann, A Berden, K Westman, P Höglund, C Stegeman, ... Arthritis & Rheumatism 64 (2), 542-548, 2012 | 395 | 2012 |
| Risk factors for relapse of antineutrophil cytoplasmic antibody–associated vasculitis M Walsh, O Flossmann, A Berden, K Westman, P Höglund, C Stegeman, ... Arthritis & Rheumatism 64 (2), 542-548, 2012 | 395 | 2012 |
| Risk factors for relapse of antineutrophil cytoplasmic antibody–associated vasculitis M Walsh, O Flossmann, A Berden, K Westman, P Höglund, C Stegeman, ... Arthritis & Rheumatism 64 (2), 542-548, 2012 | 395 | 2012 |
| Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference CM Clase, JJ Carrero, DH Ellison, ME Grams, BR Hemmelgarn, ... Kidney international 97 (1), 42-61, 2020 | 349 | 2020 |
| Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses S Schandelmaier, M Briel, R Varadhan, CH Schmid, N Devasenapathy, ... CMAJ 192 (32), E901-E906, 2020 | 340 | 2020 |
| The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis—a simulation study K Thorlund, G Imberger, M Walsh, R Chu, C Gluud, J Wetterslev, G Guyatt, ... PloS one 6 (10), e25491, 2011 | 318 | 2011 |
| Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial RB Jones, S Furuta, JWC Tervaert, T Hauser, R Luqmani, MD Morgan, ... Annals of the rheumatic diseases 74 (6), 1178-1182, 2015 | 316 | 2015 |
David JayneProfessor of Clinical Autoimmunity, University of CambridgeVerified email at cam.ac.uk
